Trevi Therapeutics Announces Publication Of Data From The CANAL Trial In IPF Chronic Cough In NEJM Evidence
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics announced positive results from the Phase 2 CANAL trial for its investigational therapy Haduvio (oral nalbuphine ER) in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial showed a rapid and marked reduction in recorded daytime cough among patients.
May 22, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevi Therapeutics' Haduvio demonstrated positive results in the Phase 2 CANAL trial for treating chronic cough in IPF patients, potentially leading to increased interest in the stock.
The positive results from the Phase 2 CANAL trial indicate that Trevi Therapeutics' Haduvio has potential in treating chronic cough in IPF patients. This could lead to increased interest in the company's stock as investors may see potential growth in the future due to the development of this therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100